Business
Plus Therapeutics adds SpectronRx for Reyobiq manufacturing
Plus Therapeutics began manufacturing activities and technology transfer with SpectronRx to support late-stage clinical supply of Reyobiq, its rhenium-186 radiopharmaceutical candidate for CNS cancers.